ClinicalTrials.gg
WithdrawnNCT03203616KIARAUpdated Nov 29, 2018

Kadcyla In pAtients With bRAin Metastasis

A Phase 2 interventional study of KADCYLA 160 MG Injection in Metastatic HER2-positive Breast Cancer With Brain Metastasis, sponsored by Jules Bordet Institute. Withdrawn. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Jules Bordet Institute · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Why this study was withdrawn
As most HER2+ patient develop brain mets while on/after having received TDM1, it has proven to be an insurmountable challenge to recruit patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.

Enrollment
54th of 56
0 · median 103
Started
2018
with 1 other
Phase 2
26 of 56
9 open now
Registered
39th of 56
by date
Lead sponsor
2 of 56
Jules Bordet Institute

Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 54th largest by enrollment, is one of 2 that started in 2018, is one of 26 in phase 2, and was the 39th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About Ado-Trastuzumab Emtansine

Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, or all of them as a file.
02

Study summary

Women with breast cancer often develop metastases in the brain. Currently, treatment of these metastases is difficult and relies on radiotherapy or surgery which often fail. Therefore, development of new methods of treatment for breast cancer with brain metastasis is very important. T-DM1 is a drug that is already in everyday use for a specific type of breast cancer called HER2-positive breast cancer. The objective of this study is to investigate whether T-DM1 is also effective in brain metastasis and can help patients to live longer and better

Read the detailed description

This is a multicentre, non-randomised, open label, single arm, phase II study of T-DM1 in patients with metastatic breast cancer and with brain metastasis who have already failed at least one line of anti-HER2 therapy for systemic disease. The study sample is composed of 2 distinct cohorts of patients.

Cohort number 1 is composed of patients with asymptomatic or oligosymptomatic brain metastasis (single or multiple), measurable according to RECIST 1.1, who have not received any local therapy (neither surgery, radiosurgery nor whole brain radiotherapy) for brain metastasis.

Cohort number 2 is composed of patients with brain metastasis (single or multiple), measurable according to RECIST 1.1, previously treated with local therapy (surgery, radiosurgery or whole brain radiotherapy) and with radiologically confirmed brain progression, with a minimum period of 3 months between the end of local therapy and brain progression.

A total number of 110 are planned for screening, in order to enrol 97 patients. A minimum of 87 evaluable patients is necessary. Inclusion of patients in both cohorts will follow a two-stage Simon optimal design. During the study, both brain assessments via magnetic-resonance imaging (MRI) and systemic assessments with computerised tomography (CT) will be performed every 3 cycles (9 weeks) of therapy.

Study treatment consists of T-DM1, 3.6 mg/kg every 3 weeks. Patients will receive study medication until unacceptable toxicity, voluntary withdrawal from study treatment, disease progression, death or pregnancy, whichever occurs first. Patients who experience only progression in the brain and who receive local therapy may remain in the study until systemic progression (or any of the other reasons stated previously), at the investigator's discretion.

After the end of study treatment, all patients will have a safety visit within 30 days (+/- 7 days) from the last T-DM1 administration date. After the safety visit, according the reason of end of study treatment, the follow-up period will begin, as described below:

  • If study treatment stopped due to progression of disease Patients will enter directly in survival follow-up. No visits are mandatory per protocol after the safety visit. Chart review and/or phone call to check if the patient is still alive are to be performed, every 6 months, in order to acquire data for the overall survival endpoint. Patients in survival follow-up who are of childbearing potential must be tested for pregnancy at 3 months and at 7 months after end of study treatment. These tests can be ordered by the investigator during regular out of study follow-up visits.
  • If study treatment stopped for any other reason than progression (either toxicity or voluntary withdrawal from study treatment) Patients will enter first in efficacy follow-up after the safety visit and then in survival follow-up when progression disease is observed.

During efficacy follow-up, 9 weekly efficacy assessments continue according to the same timetable they would have followed had treatment interruption not occurred. This consists of imaging assessments (MRI and CT) and medical visits, as well as QoL evaluations. During this period, treatment is at the discretion of the local physician/investigator.

This follow-up is to continue until disease progression or until voluntary withdrawal of the patient from the study. In case this follow-up is impossible (due to patient refusing to perform assessments or other reasons), survival data can be collected every 6 months via chart review or telephone. Patients in follow-up who are of childbearing potential must be tested for pregnancy at 3 months and at 7 months after end of study treatment. Once a patient has progressed while on efficacy follow-up, they will enter into survival follow-up as per description above.

03

Conditions studied

  • Metastatic HER2-positive Breast Cancer With Brain Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all these criteria in order to be eligible for the study:

General Criteria:

  • Female patients (≥ 18 years);
  • confirmed -positive breast cancer patients (IHC 3+ and/or ISH positive);
  • Patients should have previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or disease, or developed disease recurrence during or within six months of completing therapy;
  • At least one measurable as defined by 1.1 (≥ 10 mm);
  • Any hormone receptor status;
  • Predicted > 3 months;
  • Any previous anti-HER2 therapies are allowed, other than T-DM1;
  • performance score 0-2;
  • No significant cardiac history and a current ≥ 50%. LVEF should be determined within 21 days before enrolment;
  • Adequate organ function, evidenced by the following laboratory results. Exams are to be performed at a maximum of 7 days before enrolment.

    • > 1,500 cells/mm3 without growth factor support (14 days after last peg-filgrastrim, 7 days for regular filgrastrim).
    • count > 100,000 cells/mm3 without transfusion 2 weeks prior assessment
    • > 9 g/dL without transfusion 2 weeks prior assessment.
    • and alanine aminotransferase \< 2.5 x (ULN).
    • Total ≤ 1.5 x ULN unless the patient has documented Gilbert's syndrome, in which case direct (conjugated) bilirubin level needs to be within normal limits.
    • Serum alkaline phosphatase ≤ 2.5 x ULN. Patients with bone metastases: alkaline phosphatase ≤ 5 x ULN.
    • Serum creatinine \< 2.0 mg/dL or \< 177 μmol/L.
    • (INR) and activated partial thromboplastin time or partial thromboplastin time \< 1.5 ULN unless patient receiving anticoagulant therapy
  • For women of a serum pregnancy test will be done up to 7 days before enrolment (and it must be negative) and an agreement to use one highly-effective form of non-hormonal (true abstinence, vasectomy, oophorectomy/hysterectomy, IUD) or two effective forms of non-hormonal contraception (e.g., condoms plus spermicidal agent) at study entry (to be put in place within 2 weeks prior to enrolment), during the administration of T-DM1 and for 7 months after the last administration of T-DM1 will be obtained
  • Signed obtained before any study-specific procedure;
  • Able and willing to comply with the protocol; including the willingness to provide samples (primary if available and blood) for translational research.

Cohort 1 additional specific criteria:

  • No at enrolment
  • Oligosymptomatic or asymptomatic brain metastases not requiring immediate local therapy.

Cohort 2 additional specific criteria:

  • Radiologically confirmed brain progression after previous local therapy (neurosurgery, radiosurgery to the brain, stereotactic radiotherapy to the brain, or whole brain radiotherapy) with at least 3 months between end of local therapy and brain progression.
  • Decreasing corticosteroid dose or stable dose for at least one week prior to enrolment

Exclusion criteria

Exclusion Criteria:

Patients who exhibit any of the following conditions at screening will be ineligible for admission into the study:

General Criteria:

  • Single with indication of surgical resection
  • Pregnant or breast-feeding women
  • Documented
  • Having received any therapy within ≤ 28 days or 5 half-lives at ICF signature, whichever is longer
  • Having received hormonal therapy within 14 days of enrolment
  • Having received trastuzumab within 21 days of enrolment
  • Prior enrolment in a T-DM1-containing study, regardless of whether the patient received T-DM1 or not
  • History of intolerance (including Grade 3 or 4 infusion reaction) or to trastuzumab or murine proteins or any component of the product.
  • Current peripheral neuropathy of Grade ≥ 3 according to National Cancer Institute (NCI CTCAE) v.4.0.3
  • History of other within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those mentioned above.
  • Current unstable ventricular arrhythmia requiring treatment.
  • History of symptomatic congestive heart failure (CHF) ( [NYHA] Classes II-IV).
  • History of myocardial infarction or unstable angina within 6 months prior to first study drug administration.
  • Current dyspnoea at rest due to complications of advanced malignancy or currently requiring continuous oxygen therapy.
  • Current severe, uncontrolled systemic disease other than cancer (e.g., pulmonary, hypertension or metabolic disease)
  • Concurrent, serious, uncontrolled infections or current known infection with , active and/or .
  • Major surgical procedure or significant traumatic injury within 28 days before enrolment or anticipation of the need for major surgery during the course of study treatment.
  • Known for undergoing MRI or CT, including to receive contrast media,

Cohort 1 : additional specific criteria:

  • Previous neurosurgery or radiotherapy (radiosurgery, stereotactic radiotherapy, whole brain radiotherapy) to the brain Cohort 2 : no additional specific criteria
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Kadcyla (T-DM1)

    trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected

    Drug: KADCYLA 160 MG Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Benefit (CB)

    defined as complete response plus partial response plus stable disease in the brain, measured by RECIST 1.1, as determined by the local investigators.

    Time frame: 9 weeks

Secondary outcomes

  1. CB in the brain RECIST 1.1

    measured by RECIST 1.1 criteria, as determined by central evaluation

    Time frame: 9 weeks

  2. CB in the brain RANO

    measured by RANO brain metastases criteria, as determined by the local investigators

    Time frame: 9 weeks

  3. General and cardiac-specific safety

    AEs and SAEs according NCI-CTCAE v4.03

    Time frame: up to 30 days after last treatment administration

  4. CB: Systemic

    defined as complete response plus partial response plus stable disease in non brain areas

    Time frame: 9 weeks

  5. CB: bi-compartmental

    defined as complete response plus partial response plus stable disease in the whole body

    Time frame: 9 weeks

  6. Overall Response (OR) in the brain

    defined as complete response plus partial response in brain

    Time frame: 9 weeks

  7. Overall Response (OR) systemic

    defined as complete response plus partial response in non brain

    Time frame: 9 weeks

  8. Overall Response (OR) bi-compartmental

    defined as complete response plus partial response in the whole body

    Time frame: 9 weeks

  9. Best Response (BR) in the brain

    defined as the best obtained response in the brain

    Time frame: 1 year

  10. Best Response (BR) systemic

    defined as the best obtained response in the non brain

    Time frame: 1 year

  11. Best Response (BR) bi-compartmental

    defined as the best obtained response in the whole body

    Time frame: 1 year

  12. Brain Progression free survival (PFS)

    defined as time between enrolment in the study and progression in the brain

    Time frame: 1 year

  13. Systemic PFS

    defined as time between enrolment in the study and progression in areas other than the brain

    Time frame: 1 year

  14. Bi-compartmental PFS

    defined as time between enrolment in the study and progression of disease

    Time frame: 1 year

  15. Duration of response in the brain

    defined as time from documentation of tumour response in the brain (PR or CR) to disease progression in the brain

    Time frame: 1 year

  16. Duration of response systemic

    systemic defined as time from documentation of non-brain tumour response (PR or CR) to non-brain progression

    Time frame: 1 year

  17. Duration of response bi-compartmental

    Bi-compartmental defined as time between response and progression

    Time frame: 1 year

  18. Duration of Clinical Benefit (DCB) in the brain

    defined as the time elapsed between determination of SD, PR or CR and determination of disease progression in the brain

    Time frame: 1 year

  19. Duration of Clinical Benefit (DCB) systemic

    defined as the time elapsed between determination of SD, PR or CR and determination of systemic disease progression

    Time frame: 1 year

  20. Duration of Clinical Benefit (DCB) bi-compartmental

    defined as the time elapsed between determination of SD, PR or CR and determination of bi-compartmental disease progression

    Time frame: 1 year

  21. Overall survival

    defined as time between enrolment in the study and death

    Time frame: 1 year

  22. Quality of life

    Quality of life will be assessed using the EORTC validated questionnaires

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Aug 2018, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2017
First posted
Jun 29, 2017
StartActual
Feb 23, 2018
Primary completionActual
Aug 27, 2018
CompletionActual
Aug 27, 2018
Last update
Nov 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03203616
Responsible party
Sponsor
First posted
Jun 29, 2017
Start date
Feb 23, 2018
Primary completion
Aug 27, 2018
Completion
Aug 27, 2018
Last update
Nov 29, 2018

Study contacts

Evandro de Azambuja, MD
study chair · Jules Bordet Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ado-Trastuzumab Emtansine

Start the discussion